5HT3-receptor antagonists as antiemetics in cancer. Drug and Therapeutics Bulletin 2005;43(8):57-62.

American Gastroenterological Association medical position statement: nausea and vomiting. Gastroenterology 2001;120(1):261-3.

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8.

Nausea and vomiting. Helsinki: Duodecim Medical Publications Ltd.; 2004 June 19.

5HT3-receptor antagonists as antiemetics in cancer. Drug and Therapeutics Bulletin 2005;43(8):57-62.

Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91(3):693-700.

Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54(4):455-60.

Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102(6):1094-100.

Dhir R, Richter JE. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J Clin Gastroenterol 2004;38(3):237-42.

Dib JG, El-Saddik RA. Ginger for nausea and vomiting in pregnancy. J Pharm Pract Res 2004;34(4):305-7.

Ferdinands MD, Seneviratne J, White O. Visual deterioration in hyperemesis gravidarum. Med J Aust 2005;182(11):585-6.

Figueredo E, Canosa L. Prophylactic ondansetron for postoperative emesis. Meta-analysis of its effectiveness in patients with previous history of postoperative nause and vomiting. Acta Anaesthesiol Scand 1999;43(6):637-44.

Fleisher LA. Evidence-Based Practice of Anesthesiology, 1st ed. Philadelphia: Saunders,  2004:130-5.

Frazee LA, Mauro LS. Erythromycin in the treatment of diabetic gastroparesis. Am J Ther 1994;1(4):287-95.

Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003;97(1):62-71, table of contents.

Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17(9):2971-94.

Habib A, Gan TJ. What is the best strategy to prevent PONV? Evidence-based practice of anesthesiology 2004:130-5.

Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth 2000;47(6):537-51.

Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2002(1):CD000145.

Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2003(4):CD000145.

Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24(18):2932-47.

LA F. Evidence-based practice of anesthesiology (pp130-5). 1st ed. Philadelphia: Saunders; 2004.

Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999;88(6):1362-9.

Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003;98(2):259-63.

Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol 2006;101(5):1129-39.

Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology 2004;127(5):1589-91.

Quaynor H, Raeder JC. Incidence and severity of postoperative nausea and vomiting are similar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies. Acta Anaesthesiol Scand 2002;46(1):109-13.

Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17(1):20-8.

Shepherd S, Anderson A. Gastrointestinal nutrition: Comprehensive guide to the dietary management of diseases of the gastrointestinal tract. Melbourne: MMC Publishing; 2003.

Smith DS, Ferris CD. Current concepts in diabetic gastroparesis. Drugs 2003;63(13):1339-58.

Spitzer TR, Grunberg SM, Dicato MA. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting. Support Care Cancer 1998;6(3):233-6.

Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130(5):1466-79.

Tramer MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand 2001;45(1):4-13.

Wallenborn J, Gelbrich G, Bulst D, Behrends K, Wallenborn H, Rohrbach A, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006;333(7563):324.

White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology 2005;102(6):1101-5.

American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005;129:1753-5.

Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111(1):85-92.

Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord 2002;2(1):20-33.

Cezard JP. Managing gastro-oesophageal reflux disease in children. Digestion 2004;69 Suppl 1:3-8.

Cheung KM, Tse PW, Ko CH, Chan YC, Leung CY, Chan KH. Clinical efficacy of proton pump inhibitor therapy in neurologically impaired children with gastroesophageal reflux: prospective study. Hong Kong Med J 2001;7(4):356-9.

Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):1-16.

[URL]

Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, van Tonningen MR, Clementi M, et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005;21(3):269-75.

Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003;5(1):25-40.

Gold BD. Review article: epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther 2004;19 Suppl 1:22-7.

Institute for Clinical Systems Improvement. Dyspepsia and GERD. 6th edition. Bloomington: Institute for Clinical Systems Improvement; 2004 July.

Isolauri J. Dysphagia. Helsinki: Duodecim Medical Publications Ltd.; 2004 June 10.

Kahrilas PJ. Review article: is stringent control of gastric pH useful and practical in GERD? Aliment Pharmacol Ther 2004;20 Suppl 5:89-94; discussion 5-6.

Katelaris P, Holloway R, Talley N, Gotley D, Williams S, Dent J. Gastro-oesophageal reflux disease in adults: Guidelines for clinicians. J Gastroenterol Hepatol 2002;17(8):825-33.

Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14(6):651-68.

Lehtola J. Heartburn; reflux oesophagitis. Helsinki: Duodecim Medical Publications Ltd.; 2005 March 5.

Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003;143(2):219-23.

New Zealand Guidelines Group (NZGG). Management of dyspepsia and heartburn. Wellington: New Zealand Guidelines Group (NZGG); 2004 June 28.

Orenstein SR, Blumer JL, Faessel HM, McGuire JA, Fung K, Li BU, et al. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2002;16(5):899-907.

Orenstein SR, Gremse DA, Pantaleon CD, Kling DF, Rotenberg KS. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005;27(4):472-83.

Pikkarainen P. Dyspepsia. Helsinki: Duodecim Medical Publications Ltd.; 2004 August 25.

Safadi BY. Laparoscopic antireflux surgery. Minerva Chir 2004;59(5):447-59.

Scottish Intercollegiate Guidelines Network (SIGN). Dyspepsia: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2003 March.

[pdf] (Quick Reference Guide)

Shimatani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004;19(1):113-22.

Stein HJ, DeMeester TR. Who benefits from antireflux surgery? World J Surg 1992;16(2):313-9.

Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57(4):422-8.

van der Peet DL, Klinkenberg-Knol EC, Eijsbouts QA, van den Berg M, de Brauw LM, Cuesta MA. Laparoscopic Nissen fundoplication for the treatment of gastroesophageal reflux disease (GERD). Surgery after extensive conservative treatment. Surg Endosc 1998;12(9):1159-63.

Zimmermann AE, Walters JK, Katona BG, Souney PE, Levine D. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001;23(5):660-79; discussion 45.

ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999;56(4):347-79.

Melena. Helsinki: Duodecim Medical Publications Ltd.; 2004 October 31.

American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005;129:1753-5.

H. pylori eradication in NSAID-associated ulcers. Drug and Therapeutics Bulletin 2005;43(5):37-40.

Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005;21(6):677-86.

Bytzer P, Teglbjaerg PS. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001;96(5):1409-16.

Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang B, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002;97(9):2208-14.

Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19(10):1051-61.

Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004;127(4):1038-43.

Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359(9300):9-13.

Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87(12):1716-27.

Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. Clinical Evidence; 2004.

[URL]

Diz-Lois Palomares MT, Souto Ruzo J, Yanez Lopez JA, Alvarez Garcia A, Arnal Monreal F, Vazquez-Iglesias JL. Early-stage gastric MALT lymphomas: eradication of H. pylori and outcome. Rev Esp Enferm Dig 2002;94(11):669-78.

Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: a consensus statement. European Paediatric Task Force on Helicobacter pylori. J Pediatr Gastroenterol Nutr 2000;30(2):207-13.

Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med 2004;32(6):1277-83.

Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53(1):34-7.

Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004(4):CD003840.

Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128(7):1838-44.

Gessner BD, Bruce MG, Parkinson AJ, Gold BD, Muth PT, Dunaway E, et al. A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection. Clin Infect Dis 2005;41(9):1261-8.

Gisbert JP, Hermida C, Pajares JM. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? Hepatogastroenterology 2001;48(41):1383-8.

Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001;13(11):1303-7.

Goh KL, Navaratnam P, Peh SC, Wong NW, Chuah SY, Rahman NA, et al. Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. Eur J Gastroenterol Hepatol 1996;8(5):421-3.

Gold BD, Colletti RB, Abbott M, Czinn SJ, Elitsur Y, Hassall E, et al. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31(5):490-7.

Gottrand F, Kalach N, Spyckerelle C, Guimber D, Mougenot JF, Tounian P, et al. Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. J Pediatr 2001;139(5):664-8.

Gotzsche PC. Non-steroidal anti-inflammatory drugs. Clinical Evidence; 2004. www.clinicalevidence.com/ceweb/conditions/msd/1108/1108_I2.jsp

Howden CW, Leontiadis GI. Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease. Best Pract Res Clin Gastroenterol 2001;15(3):401-12.

Hsu CC, Lu SN, Changchien CS. One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on Helicobacter pylori eradication and ulcer healing. Hepatogastroenterology 2003;50(53):1731-4.

Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999;13(6):719-29.

Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359(9300):14-22.

Hung LC, Ching JY, Sung JJ, To KF, Hui AJ, Wong VW, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005;128(7):1845-50.

Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci 2005;50(7):1185-93.

Juni P, Rutjes AW, Dieppe PA Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002; 324:1287-8.

Katelaris PH, Adamthwaite D, Midolo P, Yeomans ND, Davidson G, Lambert J. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. Aliment Pharmacol Ther 2000;14(6):751-8.

Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002;123(6):1763-9.

Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol 2005;20(1):11-25.

Lad R, Armstrong D. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. Can J Gastroenterol 1999;13(2):135-42.

Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther 2003;18(8):829-36.

Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346(26):2033-8.

Lane JA, Murray LJ, Noble S, Egger M, Harvey IM, Donovan JL, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. BMJ 2006;332(7535):199-204.

Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343(5):310-6.

Lazzaroni M, Bianchi Porro G. Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects. Dig Liver Dis 2001;33 Suppl 2:S44-58.

Lee SK, Lee YC, Chung JB, Chon CY, Moon YM, Kang JK, et al. Low grade gastric mucosa associated lymphoid tissue lymphoma: treatment strategies based on 10 year follow-up. World J Gastroenterol 2004;10(2):223-6.

Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004(3):CD002094.

Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005;330(7491):568.

Malfertheiner P, J MO, Fischbach W, Layer P, Leodolter A, Stolte M, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003;18(6):615-25.

Malfertheiner P, Megraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997;9(1):1-2.

Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16(2):167-80.

Massimo Claar G, Monaco S, Del Veccho Blanco C, Capurso L, Fusillo M, Annibale B. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1998;12(5):463-8.

Matikainen M. Haematemesis. Helsinki: Duodecim Medical Publications Ltd.; 2005 April 17.

Matsukawa Y, Tomita Y, Nishinarita S, Horie T, Kato K, Arakawa Y, et al. Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing. J Int Med Res 1997;25(4):190-5.

McColl KE. Helicobacter pylori negative ulcer disease. Dig Liver Dis 2000;32(2):125-7.

McColl KE, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ 2002;324(7344):999-1002.

Miyake K, Tsukui T, Futagami S, Tatsuguchi A, Shinoki K, Hiratsuka T, et al. Effect of acid suppression therapy on development of gastric erosions after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16 Suppl 2:210-6.

Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005(1):CD002096.

Nakayama Y, Graham DY. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther 2004;2(4):599-610.

Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89(18):1350-5.

Ong SP, Duggan A. Eradication of Helicobacter pylori in clinical situations. Clin Exp Med 2004;4(1):30-8.

Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96(1):58-62.

Peura DA. The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14(1):109-17.

Pikkarainen P. Treatment of dyspepsia, peptic ulcer and helicobacter infection. Helsinki: Duodecim Medical Publications Ltd.; 2004 June 23.

Roher HD, Verreet PR, Wormer O, Muller FP, Ohmann C, Fischbach W. Helicobacter pylori in the upper gastrointestinal tract: medical or surgical treatment of gastric lymphoma? Langenbecks Arch Surg 2000;385(2):97-105.

Scottish Intercollegiate Guidelines Network (SIGN). Dyspepsia: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2003 March.

[pdf] (Quick Reference Guide)

Sherman P HE, Hunt RH, Fallone CA, et al. Canadian Helicobacter Study Group Consensus Conference on the approach to Helicobacter pylori infection in children and adolescents. Canadian Journal of Gastroenterology 1999;13(7):553-9.

Singapore Ministry of Health. Clinical practice guidelines: management of Helicobacter pylori infection. Singapore: Singapore Ministry of Health; 2004 September.

Sung JJ, Chan FK, Lau JY, Yung MY, Leung WK, Wu JC, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. Ann Intern Med 2003;139(4):237-43.

Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6(8):639-42.

Yeomans N, Dooley H, Lee A, Talley NJ, Katelaris PH. Helicobacter pylori: guidelines for health care providers. Sydney: Gastroenterology Society of Australia; 1999.

Anthony H, Collins CE, Davidson G, Mews C, Robinson P, Shepherd R, et al. Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia. J Paediatr Child Health 1999;35(2):125-9.

Ayub K, Imada R, Slavin J. Endoscopic retrograde cholangiopancreatography in gallstone-associated acute pancreatitis. Cochrane Database Syst Rev 2004(4):CD003630.

Bank S, Singh P, Pooran N, Stark B. Evaluation of factors that have reduced mortality from acute pancreatitis over the past 20 years. J Clin Gastroenterol 2002;35(1):50-60.

Bassi C, Falconi M, Talamini G, Uomo G, Papaccio G, Dervenis C, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998;115(6):1513-7.

Bassi C, Pederzoli P, Vesentini S, Falconi M, Bonora A, Abbas H, et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother 1994;38(4):830-6.

Bosscha K, Vos A, Visser MR, Berger P, van Dullemen H, Ploeg RJ, et al. [Reduced risk of complications associated with severe acute (necrotizing) pancreatitis by administration of antibiotics; results from a literature review]. Ned Tijdschr Geneeskd 2001;145(41):1982-5.

Buchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992;103(6):1902-8.

Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996;13(2):198-201.

Dervenis C, Bassi C. Evidence-based assessment of severity and management of acute pancreatitis. Br J Surg 2000;87(3):257-8.

Dugernier T, Reynaert M, Laterre PF. Early multi-system organ failure associated with acute pancreatitis: a plea for a conservative therapeutic strategy. Acta Gastroenterol Belg 2003;66(2):177-83.

Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: A meta-analysis. J Gastrointest Surg 1998;2(6):496-503.

Guda NM, Freeman ML, Smith C. Role of extracorporeal shock wave lithotripsy in the treatment of pancreatic stones. Rev Gastroenterol Disord 2005;5(2):73-81.

Guda NM, Partington S, Freeman ML. Extracorporeal shock wave lithotripsy in the management of chronic calcific pancreatitis: a meta-analysis. Jop 2005;6(1):6-12.

Ho HS, Frey CF. The role of antibiotic prophylaxis in severe acute pancreatitis. Arch Surg 1997;132(5):487-92; discussion 92-3.

Inui K, Tazuma S, Yamaguchi T, Ohara H, Tsuji T, Miyagawa H, et al. Treatment of pancreatic stones with extracorporeal shock wave lithotripsy: results of a multicenter survey. Pancreas 2005;30(1):26-30.

Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004;126(4):997-1004.

Levy P, Heresbach D, Pariente EA, Boruchowicz A, Delcenserie R, Millat B, et al. Frequency and risk factors of recurrent pain during refeeding in patients with acute pancreatitis: a multivariate multicentre prospective study of 116 patients. Gut 1997;40(2):262-6.

Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995;222(1):57-65.

Lund H, Tonnesen H, Tonnesen MH, Olsen O. Long-term recurrence and death rates after acute pancreatitis. Scand J Gastroenterol 2006;41(2):234-8.

Niederau C, Hippenstiel J. Conservative management of acute pancreatitis: complications and outcome in a community-based hospital. Pancreas 2006;32(1):67-79.

Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis--a single-center randomized study. J Gastrointest Surg 2001;5(2):113-8; discussion 8-20.

Pitchumoni CS, Patel NM, Shah P. Factors influencing mortality in acute pancreatitis: can we alter them? J Clin Gastroenterol 2005;39(9):798-814.

Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993;176(5):480-3.

Pitchumoni CS, Patel NM, Shah P. Factors influencing mortality in acute pancreatitis: can we alter them? J Clin Gastroenterol 2005;39(9):798-814.

Renzulli P, Jakob SM, Tauber M, Candinas D, Gloor B. Severe acute pancreatitis: case-oriented discussion of interdisciplinary management. Pancreatology 2005;5(2-3):145-56.

Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995;346(8976):663-7.

Schwarz M, Isenmann R, Meyer H, Beger HG. [Antibiotic use in necrotizing pancreatitis. Results of a controlled study]. Dtsch Med Wochenschr 1997;122(12):356-61.

Sharma VK, Howden CW. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas 2001;22(1):28-31.

Tadenuma H, Ishihara T, Yamaguchi T, Tsuchiya S, Kobayashi A, Nakamura K, et al. Long-term results of extracorporeal shockwave lithotripsy and endoscopic therapy for pancreatic stones. Clin Gastroenterol Hepatol 2005;3(11):1128-35.

Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 2001;96(4):1266-72.

Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: An update. J Clin Gastroenterol 2005;39(8):709-16.

Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2003(4):CD002941.

Ahn J, Flamm S. Peginterferon-alpha(2b) and ribavirin. Expert Rev Anti Infect Ther 2004;2(1):17-25.

Arenas JI, Vargas HE. Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterol Clin North Am 2004;33(3):549-62, ix.

ASHM. Coinfection - HIV and viral hepatitis: A guide for clinical management. 2005.

[URL]

Australian Technical Advisory Group on Immunisation. The Australian immunisation handbook. 8th ed. Canberra: Commonwealth of Australia; 2003.

Bozkaya H, Yurdaydin C, Idilman R, Tuzun A, Cinar K, Erkan O, et al. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther 2005;10(2):319-25.

Brook MG, Gilson R, Wilkins E. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). HIV Medicine 2005;6(s2):84-95.

Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005;3(2):241-9.

Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002;36(5 Suppl 1):S135-44.

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001-10.

Chien RN, Liaw YF. Thymalfasin for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004;2(1):9-16.

Cooksley WG. Treatment of hepatitis B with interferon and combination therapy. Clin Liver Dis 2004;8(2):353-70.

Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004;24 Suppl 1:45-53.

Cooper CL. Therapies for HIV and viral hepatitis coinfection. Expert Rev Anti Infect Ther 2005;3(1):81-9.

Coursaget P, Yvonnet B, Chotard J, Vincelot P, Sarr M, Diouf C, et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987;22(1):1-5.

Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40(6):1260-5.

Daugherty T, Bonacini M. Therapy of hepatitis C in patients with HIV infection. Expert Rev Anti Infect Ther 2005;3(3):375-84.

Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38(3):645-52.

Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40(4):883-91.

Dore G, Grulich A, Kidd M, Hoy J, McCoy R, Mijch A, et al., editors. HIV/viral hepatitis: a guide for primary care. 2nd ed. Sydney: Australasian Society for HIV Medicine (ASHM); 2004.

Dore GJ, Sasadeusz J, editors. Coinfection. HIV and viral hepatitis: a guide for clinical management. Sydney: Australasian Society for HIV Medicine Inc.; 2003.

Durantel D, Escuret V, Zoulim F. Current and emerging therapeutic approaches to hepatitis C infection. Expert Rev Anti Infect Ther 2003;1(3):441-54.

EASL Jury. EASL International Consensus Conference on Hepatitis B: 13-14 September, 2002 Geneva, Switzerland consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3-S25.

Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004;126(7):1740-9.

Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123(3):719-27.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82.

Fung SK, Lok AS. Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol 2004;2(10):839-48.

Hadziyannis SJ, Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004;2(4):475-83.

Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352(26):2673-81.

Hann HW, Jonsson Funk ML, Rosenberg DM, Davis R. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol 2005;20(3):433-40.

Hardikar W, Elliott EJ, Jones CA. The silent infection: Should we be testing for perinatal hepatitis C and, if so, how? Med J Aust 2006;184(2):54-5.

Hartman C, Berkowitz D, Shouval D, Eshach-Adiv O, Hino B, Rimon N, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 2003;22(3):224-9.

Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42(1):63-71.

Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, Huo TI, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003;10(4):277-84.

Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005;22(6):519-28.

Hui CK, Zhang HY, Lau GK. Management of chronic hepatitis B in treatment-experienced patients. Gastroenterol Clin North Am 2004;33(3):601-16, x.

Jefferson T, Demicheli V, Deeks J, MacMillan A, Sassi F, Pratt M. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 2000(2):CD000100.

Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130(3):632-8.

Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004;2(5):745-60.

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2(2):87-106.